摘要
目的探讨左西孟旦治疗失代偿性心力衰竭的临床效果及不良反应。方法选取2012年3月—2013年3月我院收治的失代偿性心力衰竭患者72例,将其随机分为试验组38例和对照组34例,对照组在常规治疗的基础上予以多巴酚丁胺治疗,试验组在常规治疗的基础上予以左西孟旦注射液治疗,比较两组的临床疗效,并观察两组不良反应发生率和治疗前后心功能指标改善情况,包括B型脑利钠肽(BNP)、每搏输出量(SV)和左室射血分数(LVEF)。结果对照组总有效率为73.5%(25/34),低于试验组的97.4%(37/38)(P<0.05)。治疗前两组BNP、SV及LVEF比较,差异无统计学意义(P>0.05);治疗后试验组BNP低于对照组,SV和LVEF高于对照组(P<0.05)。对照组不良反应发生率为44.1%(15/34),高于试验组的10.5%(4/38)(P<0.05)。结论左西孟旦治疗失代偿性心力衰竭能明显改善患者BNP、SV和LVEF,疗效显著,且不良反应少,值得临床进一步推广。
Objective To investigate the clinical effect and adverse reactions of Levosimendan on patients with decompensated heart failure. Methods 72 patients with decompensated heart failure admitted to our hospial from March 2011 to March 2013 were randomly divided into groups experiment（ 38 cases） and control（ 34 cases）. Both treated for conventional treatment,control group was given Dobutamine on basis of conventional treatment,experiment group was given Levosimendan on basis of conventional treatment. The clinical effect,adverse reaction and BNP,SV,LVEF between two groups were compared. Results The total efficacy of control group was 73. 5%（ 25 /34）,was lower than that of experiment group of 97. 4%（ 37 /38）（ P〈0. 05）. Before treatment,the BNP,SV and LVEF showed no significantly differences between two groups（ P〈0. 05）; after treatment,the BNP in experiment group was lower than that of control group,SV and LVEF were higher（ P〉 0. 05）. The adverse reaction of control group was 44. 1%（ 15 /34）,was higher than that of experiment group of 10. 5%（ 4 /38）（ P〈0. 05）. Conclusion Levosimendan in treating decompensated heart failure can significantly improve BNP,SV and LVEF,has a obviously effect and fewer adverse reaction,being worthy of promotion.
出处
《实用心脑肺血管病杂志》
2014年第6期12-14,共3页
Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease
关键词
心力衰竭
治疗结果
左西孟旦
不良反应
Heart failure
Treatment outcome
Levosimendan
Adverse reaction
